RFL Rafael Holdings, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1713863 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.7%
TTM net income YoY-58.3%
TTM EPS YoY44.2%
Revenue 3-yr CAGR46.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,821.2%
Net margin-3,390.7%
FCF margin—
EBITDA margin-3,797.8%
Returns
ROE-36.9%
ROA-30.1%
ROIC (approx.)-61.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio2.35x
Interest coverage-100.29x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-07-31 | FY20252025-07-31 | FY20242024-07-31 | FY20232023-07-31 | FY20222022-07-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $874,000 | $917,000 | $637,000 | $279,000 | $410,000 |
| Cost of revenue | — | — | $154,000 | — | $3.50M |
| Gross profit | — | — | $483,000 | — | -$3.09M |
| R&D expense | $24.33M | $12.82M | $4.17M | $6.31M | $8.74M |
| SG&A expense | $9.70M | $13.78M | $8.85M | $8.93M | $16.98M |
| Operating income | -$33.41M | -$29.16M | -$102.63M | -$15.04M | -$60.48M |
| Interest expense | $333,000 | $658,000 | $248,000 | — | $6,000 |
| Pretax income | -$27.97M | -$33.20M | -$67.26M | -$8.74M | -$139.97M |
| Income tax | -$13,000 | -$2.55M | -$2.68M | -$255,000 | — |
| Net income | -$29.64M | -$30.52M | -$34.41M | -$1.88M | -$124.66M |
| EBITDA | -$33.20M | -$28.87M | -$102.40M | -$14.96M | -$60.41M |
| EPS (basic) | -0.58 | -1.04 | -1.45 | -0.08 | -6.31 |
| EPS (diluted) | -0.58 | -1.04 | -1.45 | -0.08 | -6.31 |
| Weighted avg. shares (diluted) | 51.39M | 29.42M | 23.75M | 23.26M | 19.77M |
| Balance sheet | |||||
| Cash & equivalents | $22.10M | $52.77M | $2.67M | $21.50M | $26.54M |
| Short-term investments | — | — | $63.27M | $57.71M | $36.70M |
| Receivables | $444,000 | $627,000 | $426,000 | $213,000 | $157,000 |
| Inventory | $377,000 | $281,000 | — | — | — |
| Current assets | $25.82M | $56.71M | $72.50M | $82.94M | $108.35M |
| PP&E, net | $1.50M | $1.60M | $2.12M | $1.70M | $1.77M |
| Goodwill | $19.94M | $19.94M | $3.05M | — | — |
| Intangibles | $863,000 | $994,000 | $1.85M | — | — |
| Total assets | $83.06M | $114.11M | $96.83M | $98.83M | $118.32M |
| Current liabilities | $10.99M | $11.60M | $7.51M | $2.15M | $21.03M |
| Total liabilities | $11.09M | $15.74M | $10.57M | $2.20M | $21.11M |
| Shareholders' equity | $66.31M | $94.39M | $82.19M | $100.29M | $100.52M |
| Cash flow statement | |||||
| Operating cash flow | -$29.99M | -$18.92M | -$7.80M | -$10.89M | -$26.08M |
| Capital expenditure | $3,000 | $4,000 | $143,000 | — | $2,000 |
| Free cash flow | -$29.99M | -$18.93M | -$7.95M | — | -$26.08M |
| Investing cash flow | -$676,000 | $44.03M | -$10.82M | $21.21M | -$63.80M |
| Financing cash flow | -$116,000 | $24.83M | -$179,000 | -$15.22M | $103.86M |
| Depreciation & amortization | $204,000 | $288,000 | $225,000 | $78,000 | $72,000 |
| Stock-based compensation | $1.39M | $2.12M | $2.30M | $2.19M | -$917,000 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.